Close Menu

Bio-Rad

Bio-Rad's PCR-based test is designed to detect SARS-CoV-2 nucleic acid, while United Biomedical's test detects antibodies against the virus.

Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay. 

News items for the in vitro diagnostics industry for the week of Nov. 2, 2020.

Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.

The firm is using ddPCR to support testing 3,000 samples per day with a turnaround time of approximately 24 hours

The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.

According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.

Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased. 

The reimbursement rates for the most commonly performed SARS-CoV-2 serologic tests are $42.13 and $45.23, depending on the billing code used.

The listing enables assay developers and testing labs in the US to access the instrument for COVID-19 testing, the firm said.

Pages